keyword
MENU ▼
Read by QxMD icon Read
search

bcnu

keyword
https://www.readbyqxmd.com/read/28334700/single-agent-pixantrone-as-a-bridge-to-autologous-stem-cell-transplantation-in-a-patient-with-refractory-diffuse-large-b-cell-lymphoma
#1
Lorena Appio, Carlo Landoni, Maria La Targia, Vanda Bertolli, Martina Chiarucci, Giovanni Crovetti, Elisabetta Vassenna, Giovanni Serio, Marco Bregni
Aggressive non-Hodgkin lymphoma is associated with poor long-term survival after relapse or resistance to chemotherapy. We report a case of aggressive non-Hodgkin lymphoma refractory to first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and second-line R-DHAP (rituximab, dexamethasone, cytarabine, and cisplatin) chemotherapy treatments. The patient achieved remission with single-agent pixantrone, and received a consolidation with high-dose BEAM (BCNU, etoposide, cytarabine, and melphalan) chemotherapy and autologous stem cell transplantation...
March 24, 2017: Chemotherapy
https://www.readbyqxmd.com/read/28319810/inhibitors-of-glut-slc2a-enhance-the-action-of-bcnu-and-temozolomide-against-high-grade-gliomas
#2
Alberto Azzalin, Giulia Nato, Elena Parmigiani, Francesca Garello, Annalisa Buffo, Lorenzo Magrassi
Glucose transport across glioblastoma membranes plays a crucial role in maintaining the enhanced glycolysis typical of high-grade gliomas and glioblastoma. We tested the ability of two inhibitors of the glucose transporters GLUT/SLC2A superfamily, indinavir (IDV) and ritonavir (RTV), and of one inhibitor of the Na/glucose antiporter type 2 (SGLT2/SLC5A2) superfamily, phlorizin (PHZ), in decreasing glucose consumption and cell proliferation of human and murine glioblastoma cells. We found in vitro that RTV, active on at least three different GLUT/SLC2A transporters, was more effective than IDV, a specific inhibitor of GLUT4/SLC2A4, both in decreasing glucose consumption and lactate production and in inhibiting growth of U87MG and Hu197 human glioblastoma cell lines and primary cultures of human glioblastoma...
March 17, 2017: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/28267593/phase-ii-study-of-yttrium-90-ibritumomab-tiuxetan-plus-high-dose-beam-for-non-hodgkin-lymphoma-the-role-of-histology
#3
Amrita Y Krishnan, Joycelynne Palmer, Auayporn P Nademanee, Robert Chen, Leslie L Popplewell, Ni-Chun Tsai, James F Sanchez, Jennifer Simpson, Ricardo Spielberger, Dave Yamauchi, Stephen J Forman
Standard-dose (90)yttrium-ibritumomab tiuxetan (0.4 mci/kg) (Zevalin) together with high-dose BEAM (BCNU, etoposide, cytarabine, and melphalan) (Z-BEAM) has been shown to be a well-tolerated autologous hematopoietic stem cell transplantation (autoHCT) preparative regimen for non-Hodgkin lymphoma. We report the outcomes of a single-center, single-arm phase II trial of Z-BEAM conditioning in high-risk CD20(+) non-Hodgkin lymphoma histologic strata: diffuse large B cell (DLBCL), mantle cell (MCL), follicular (FL), and transformed (TF)...
March 3, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28254657/the-diverse-roles-of-glutathione-associated-cell-resistance-against-hypericin-photodynamic-therapy
#4
Theodossis A Theodossiou, Cathrine E Olsen, Marte Jonsson, Andreas Kubin, John S Hothersall, Kristian Berg
The diverse responses of different cancers to treatments such as photodynamic therapy of cancer (PDT) have fueled a growing need for reliable predictive markers for treatment outcome. In the present work we have studied the differential response of two phenotypically and genotypically different breast adenocarcinoma cell lines, MCF7 and MDA-MB-231, to hypericin PDT (HYP-PDT). MDA-MB-231 cells were 70% more sensitive to HYP PDT than MCF7 cells at LD50. MCF7 were found to express a substantially higher level of glutathione peroxidase (GPX4) than MDA-MB-231, while MDA-MB-231 differentially expressed glutathione-S-transferase (GSTP1), mainly used for xenobiotic detoxification...
February 24, 2017: Redox Biology
https://www.readbyqxmd.com/read/28218292/hyperthermia-and-chemotherapy-using-fe-salen-nanoparticles-might-impact-glioblastoma-treatment
#5
Makoto Ohtake, Masanari Umemura, Itaru Sato, Taisuke Akimoto, Kayoko Oda, Akane Nagasako, Jeong-Hwan Kim, Takayuki Fujita, Utako Yokoyama, Tomohiro Nakayama, Yujiro Hoshino, Mai Ishiba, Susumu Tokura, Masakazu Hara, Tomoya Muramoto, Sotoshi Yamada, Takatsugu Masuda, Ichio Aoki, Yasushi Takemura, Hidetoshi Murata, Haruki Eguchi, Nobutaka Kawahara, Yoshihiro Ishikawa
We previously reported that μ-oxo N,N'-bis(salicylidene)ethylenediamine iron [Fe(Salen)], a magnetic organic compound, has direct anti-tumor activity, and generates heat in an alternating magnetic field (AMF). We showed that Fe(Salen) nanoparticles are useful for combined hyperthermia-chemotherapy of tongue cancer. Here, we have examined the effect of Fe(Salen) on human glioblastoma (GB). Fe(Salen) showed in vitro anti-tumor activity towards several human GB cell lines. It inhibited cell proliferation, and its apoptosis-inducing activity was greater than that of clinically used drugs...
February 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28197307/synthesis-and-antitumor-activity-evaluation-of-a-novel-combi-nitrosourea-prodrug-bgcnu
#6
Yameng Wang, Ting Ren, Xinxin Lai, Guohui Sun, Lijiao Zhao, Na Zhang, Rugang Zhong
Chloroethylnitrosoureas (CENUs) are an important type of alkylating agent employed in the clinical treatment of cancer. However, the anticancer efficacy of CENUs is greatly decreased by a DNA repairing enzyme, O(6)-alkylguanine-DNA alkyltransferase (AGT), by preventing the formation of interstrand cross-links (ICLs). In this study, a combi-nitrosourea prodrug, namely, N-(2-chloroethyl)-N'-2-(O(6)-benzyl-9-guanine)ethyl-N-nitrosourea (BGCNU), which possesses an O(6)-benzylguanine (O(6)-BG) derivative and CENU pharmacophores simultaneously, was synthesized and evaluated for its ability to induce ICLs...
February 9, 2017: ACS Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/28143954/early-treatment-intensification-with-r-ice-and-90y-ibritumomab-tiuxetan-zevalin-beam-stem-cell-transplantation-in-patients-with-high-risk-diffuse-large-b-cell-lymphoma-patients-and-positive-interim-pet-after-4-cycles-of-r-chop-14
#7
Mark Hertzberg, Maher K Gandhi, Judith Trotman, Belinda Butcher, John Taper, Amanda Johnston, Devinder Gill, Shir-Jing Ho, Gavin Cull, Keith Fay, Geoff Chong, Andrew Grigg, Ian D Lewis, Sam Milliken, William Renwick, Uwe Hahn, Robin Filshie, George Kannourakis, Anne-Marie Watson, Pauline Warburton, Andrew Wirth, John F Seymour, Michael S Hofman, Rodney J Hicks
In the treatment of diffuse large B-cell lymphoma, a persistently positive [(18)F]fluorodeoxyglucose positron emission tomography (PET) scan typically carries a poor prognosis. In this prospective multi-center phase II study, we sought to establish whether treatment intensification with R-ICE (rituximab, ifosfamide, carboplatin, and etoposide) chemotherapy followed by 90Y-ibritumomab tiuxetan-BEAM (BCNU, etoposide, cytarabine, and melphalan) for high-risk diffuse large B-cell lymphoma patients who are positive on interim PET scan after 4 cycles of R-CHOP-14 (rituximab, cyclophosphamide, doxorubicin, and prednisone) can improve 2-year progression-free survival from a historically unfavorable rate of 40% to a rate of 65%...
February 2017: Haematologica
https://www.readbyqxmd.com/read/28112752/carmustine-replacement-in-intensive-chemotherapy-preceding-reinjection-of-autologous-hscs-in-hodgkin-and-non-hodgkin-lymphoma-a-review
#8
REVIEW
G Damaj, J Cornillon, K Bouabdallah, R Gressin, S Vigouroux, T Gastinne, F Ranchon, H Ghésquières, G Salles, I Yakoub-Agha, E Gyan
High-dose chemotherapy preceding autologous hematopoietic stem cell transplantation (auto-HSCT) is one treatment option for patients with Hodgkin (HL) or non-Hodgkin lymphoma (NHL). The most frequently used intensive chemotherapy is a combination of carmustine (BCNU), etoposide, cytarabine and melphalan (BEAM). However, BCNU is consistently in short supply, and there has been a recent dramatic increase in its cost, necessitating the utilization of conditioning alternatives. The busulfan-based conditioning regimen known as the busulfan-cyclophosphamide-etoposide (BuCyE) combination is the second most-studied conditioning regimen worldwide after BEAM, and it exhibits a benefit/risk ratio that is comparable to that of BEAM...
January 23, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28040063/pivotal-role-of-glutathione-depletion-in-enos-uncoupling-of-lps-treated-huvecs
#9
L Chen, E Liu, D Cao, S Li, C Xiao, M Xiong, Q Kou
The present study investigated the relationship between uncoupling of endothelial nitric oxide synthase (eNOS) and vascular endothelial cell (VEC) oxidative stress (OS) during sepsis and the role of eNOS glutathionylation in eNOS uncoupling of septic VECs. Human umbilical vein endothelial cells (HUVECs) cultured in vitro (EA.hy269 cell line) were incubated with Dulbecco's modified Eagle's medium (DMEM) (normal control group), lipopolysaccharide (LPS) (sepsis group), 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) (glutathionylation group), and LPS+ dithiothreitol (DTT) (deglutathionylation sepsis group)...
November 30, 2016: Cellular and Molecular Biology
https://www.readbyqxmd.com/read/28011985/beeam-conditioning-with-bendamustine-replacing-bcnu-before-autologous-transplantation-is-safe-and-effective-in-lymphoma-patients
#10
Stefanie Gilli, Urban Novak, Behrouz Mansouri Taleghani, Gabriela M Baerlocher, Kurt Leibundgut, Yara Banz, Thilo Zander, Daniel Betticher, Thomas Egger, Daniel Rauch, Thomas Pabst
BEAM with BCNU is commonly used for conditioning treatment followed by autologous stem cell transplantation (ASCT). However, pulmonary toxicity and availability issues associated with BCNU prompted us to evaluate bendamustine-replacing BCNU (BeEAM). We analyzed 39 lymphoma patients receiving BeEAM conditioning with 200 mg/m(2) bendamustine at days -7 and -6. The median duration until neutrophil recovery was 11 days, and 15 days for platelet recovery (>20 g/L). The most common grade 3/4 non-hematologic toxicities comprised mucosal side effects (27 pts...
March 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28008595/defective-expression-of-apoptosis-related-molecules-in-multiple-sclerosis-patients-is-normalized-early-after-autologous-haematopoietic-stem-cell-transplantation
#11
G L V de Oliveira, A F Ferreira, E P L Gasparotto, S Kashima, D T Covas, C T Guerreiro, D G Brum, A A Barreira, J C Voltarelli, B P Simões, M C Oliveira, F A de Castro, K C R Malmegrim
Defective apoptosis might be involved in the pathogenesis of multiple sclerosis (MS). We evaluated apoptosis-related molecules in MS patients before and after autologous haematopoietic stem cell transplantation (AHSCT) using BCNU, Etoposide, AraC and Melphalan (BEAM) or cyclophosphamide (CY)-based conditioning regimens. Patients were followed for clinical and immunological parameters for 2 years after AHSCT. At baseline, MS patients had decreased proapoptotic BAD, BAX and FASL and increased A1 gene expression when compared with healthy counterparts...
March 2017: Clinical and Experimental Immunology
https://www.readbyqxmd.com/read/27984652/a-multi-institutional-analysis-of-peritransplantation-radiotherapy-in-patients-with-relapsed-refractory-hodgkin-lymphoma-undergoing-autologous-stem-cell-transplantation
#12
Sarah A Milgrom, Shekeab Jauhari, John P Plastaras, Yago Nieto, Bouthaina S Dabaja, Chelsea C Pinnix, Grace L Smith, Pamela K Allen, J Nicholas Lukens, Amit Maity, Yasuhiro Oki, Michelle A Fanale, Sunita D Nasta
BACKGROUND: No consensus exists regarding the use of radiotherapy (RT) in conjunction with high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) for patients with relapsed/refractory classical Hodgkin lymphoma (HL). The objectives of the current study were to characterize practice patterns and assess the efficacy and toxicity of RT at 2 major transplantation centers. METHODS: Eligible patients underwent HDC/ASCT from 2006 through 2015 using the combination of either carmustine (BCNU), etoposide, cytarabine, and melphalan (BEAM) or cyclophosphamide, BCNU, and etoposide (CBV)...
December 16, 2016: Cancer
https://www.readbyqxmd.com/read/27920506/polifeprosan-20-3-85-carmustine-slow-release-wafer-in-malignant-glioma-patient-selection-and-perspectives-on-a-low-burden-therapy
#13
REVIEW
Lawrence Kleinberg
Polifeprosan 20 with carmustine (GLIADEL(®)) polymer implant wafer is a biodegradable compound containing 3.85% carmustine (BCNU, bischloroethylnitrosourea) implanted in the brain at the time of planned tumor surgery, which then slowly degrades to release the BCNU chemotherapy directly into the brain thereby bypassing the blood-brain barrier. Carmustine implant wafers were demonstrated to improve survival in randomized placebo-controlled trials in patients undergoing a near total resection of newly diagnosed or recurrent malignant glioma...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27845303/new-insights-into-estrogenic-regulation-of-o-6-methylguanine-dna-methyltransferase-mgmt-in-human-breast-cancer-cells-co-degradation-of-er-%C3%AE-and-mgmt-proteins-by-fulvestrant-or-o-6-benzylguanine-indicates-fresh-avenues-for-therapy
#14
Ameya Paranjpe, Nathan I Bailey, Santhi Konduri, George C Bobustuc, Francis Ali-Osman, Mohd A Yusuf, Surendra R Punganuru, Hanumantha Rao Madala, Debasish Basak, Agm Mostofa, Kalkunte S Srivenugopal
Endocrine therapy using estrogen receptor-α (ER-α) antagonists for attenuating horm2one-driven cell proliferation is a major treatment modality for breast cancers. To exploit any DNA repair deficiencies associated with endocrine therapy, we investigated the functional and physical interactions of ER-α with O(6)-methylguanine DNA methyltransferase (MGMT), a unique DNA repair protein that confers tumor resistance to various anticancer alkylating agents. The ER-α -positive breast cancer cell lines (MCF-7, T47D) and ER- negative cell lines (MDAMB-468, MDAMB-231), and established inhibitors of ER-α and MGMT, namely, ICI-182,780 (Faslodex) and O(6)-benzylguanine, respectively, were used to study MGMT- ER interactions...
September 2016: Journal of Biomedical Research
https://www.readbyqxmd.com/read/27758718/current-and-future-drug-treatments-for-glioblastomas
#15
REVIEW
Shigeo Ohba, Yuichi Hirose
Glioblastomas are the most aggressive of all gliomas and have the worst prognosis, with 5-year survival rates of less than 10%. Temozolomide (TMZ) is a DNA-methylating agent. Now that TMZ is available, the standard treatment is maximal safe resection, followed by treatment with radiation and TMZ. TMZ has also been used for maintenance therapy. Recently, bevacizumab, which is a monoclonal antibody to vascular endothelial growth factor, has been used for the initial treatment of glioblastomas and for the treatment of recurrent glioblastomas...
2016: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/27757721/outcome-of-patients-affected-by-newly-diagnosed-glioblastoma-undergoing-surgery-assisted-by-5-aminolevulinic-acid-guided-resection-followed-by-bcnu-wafers-implantation-a-3-year-follow-up
#16
Alessandro Della Puppa, Giuseppe Lombardi, Marta Rossetto, Oriela Rustemi, Franco Berti, Diego Cecchin, Marina Paola Gardiman, Giuseppe Rolma, Luca Persano, Vittorina Zagonel, Renato Scienza
The purpose of the study was to evaluate the clinical outcome of the association of BCNU wafers implantation and 5-aminolevulinic acid (5-ALA) fluorescence in the treatment of patients with newly diagnosed glioblastoma (ndGBM). Clinical and surgical data from patients who underwent 5-ALA surgery followed by BCNU wafers implantation were retrospectively evaluated (20 patients, Group I) and compared with data of patients undergoing surgery with BCNU wafers alone (42 patients, Group II) and 5-ALA alone (59 patients, Group III)...
October 18, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27699999/outpatient-administration-of-beam-conditioning-prior-to-autologous-stem-cell-transplantation-for-lymphoma-is-safe-feasible-and-cost-effective
#17
Robin M Reid, Andrea Baran, Jonathan W Friedberg, Gordon L Phillips, Jane L Liesveld, Michael W Becker, Lucy Wedow, Paul M Barr, Laurie A Milner
High-dose BEAM chemotherapy (BCNU, etoposide, Ara-C, and melphalan) followed by autologous hematopoietic stem cell transplantation is frequently used as consolidative therapy for patients with recurrent or refractory Hodgkin or non-Hodgkin lymphoma. The BEAM regimen has traditionally been administered over 6 days in the hospital, with patients remaining hospitalized until hematologic recovery and clinical stability. In an effort to reduce the length of hospitalization for these patients, our institution has transitioned from inpatient (IP) to outpatient (OP) administration of BEAM conditioning...
November 2016: Cancer Medicine
https://www.readbyqxmd.com/read/27646474/irgd-mediated-core-shell-nanoparticles-loading-carmustine-and-o-6-benzylguanine-for-glioma-therapy
#18
Chang Liu, Sen Yao, Xuqian Li, Feng Wang, Yanyan Jiang
iRGD (internalizing RGD) with high affinity to αν integrins was reported to enhance tumor penetrability by binding to neuropilin-1 (NRP-1). Based on our previous study, chitosan surface-modified poly (lactide-co-glycolides) nanoparticles (PLGA/CS NPs), loaded with carmustine (BCNU) and its sensitizer (O(6)-benzylguanine, BG) showed stronger anti-tumor effect than free drugs. In present study, PLGA/CS NPs (NPs) with core-shell structure were prepared and modified with iRGD or mPEG. F98, C6 or U87 cell lines with different receptors levels were selected for in vitro and in vivo studies...
October 6, 2016: Journal of Drug Targeting
https://www.readbyqxmd.com/read/27620713/decitabine-prior-to-salvaged-unrelated-cord-blood-transplantation-for-refractory-or-relapsed-childhood-acute-leukemia
#19
Haixia Zhou, Changcheng Zheng, Xiaoyu Zhu, Baolin Tang, Juan Tong, Xuhan Zhang, Lei Zhang, Huilan Liu, Zimin Sun
No clinical studies have investigated the role of decitabine as a part of the myeloablative conditioning regimen prior to UCBT for refractory or relapsed childhood AL in patients in NR status. The aim of this study was to identify the potential benefits of decitabine as a prior therapy before salvaged unrelated UCBT for refractory or relapsed childhood AL. Eight consecutive patients with childhood refractory/relapsed AL were enrolled in our study between 2013 and 2014. All patients were in NR status before the time of transplant and had features associated with poor outcomes, such as CNSL, MDS-AML, high WBC count at diagnosis, and hypodiploid status (FLT3+/ITD+)...
December 2016: Pediatric Transplantation
https://www.readbyqxmd.com/read/27614867/infusion-reactions-are-common-after-high-dose-carmustine-in-beam-chemotherapy-and-are-not-reduced-by-lengthening-the-time-of-administration
#20
Sarah Perreault, Julie Baker, Erin Medoff, Kathryn Pratt, Francine Foss, Iris Isufi, Stuart Seropian, Dennis L Cooper
PURPOSE: Carmustine (BCNU) is used in the conditioning regimens BEAM and CBV for autologous stem cell transplantation. Carmustine-related infusion reactions, while not described in the BEAM literature, occurred in 95 % of patients who received CBV. The most common symptoms include flushing, facial pain, headache, and hypotension. These reactions have been attributed to the absolute ethanol that is used in the reconstitution process or alternatively by a direct effect of carmustine. It is currently recommended that carmustine 300 mg/m(2) be infused over at least 100 min (3-5 mg/m(2)/min)...
January 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
keyword
keyword
54805
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"